Sells biosimulation software, scientific data tools and consulting services to biopharmaceutical and biotech companies for drug research, development and regulatory submissions.
10-K for FY2025, filed Feb 26, 2026We are a global leader in biosimulation science, technology, and consulting services for using Model-Informed Drug Development (“MIDD”) in…View ↗
We offer differentiated and comprehensive solutions for MIDD, which include science, technology and consulting services. Customers leverage…View ↗
Our data suite allows customers to efficiently standardize preclinical and clinical data during the drug development process, utilize that…View ↗
Our comprehensive regulatory science solutions provide our customers the coordinated technology-enabled regulatory submission and…View ↗
Customers buy software licenses, cloud subscriptions, maintenance and consulting; subscriptions and support are generally billed in advance, while service work is billed periodically or at milestones as it progresses.
10-K for FY2025, filed Feb 26, 2026The Company’s revenue consists of fees for perpetual and term licenses for its software products, post-contract customer support (referred…View ↗
The Company’s primary professional services offering includes consulting services, which may be either strategic consulting services…View ↗
Software license revenue consists primarily of sales of software licenses downloaded and installed by our customers on their own hardware.…View ↗
SaaS revenue consists of subscription fees for access to, and related support for, the Company’s cloud-based solutions. The Company…View ↗
The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract…View ↗
Contract assets relate to the Company’s rights to consideration for performance obligations satisfied but not billed at the reporting date…View ↗
$418.8M
10-K for FY2025, filed Feb 26, 2026
$418.8M ↗
Drug developers and research organizations, academic and government institutions, and regulators use Certara’s software and services. Its commercial team works directly with customers and may use software distributors in some regions or categories.
10-K for FY2025, filed Feb 26, 2026
Not on paper. It lost $1.6M in FY2025, but brought in more cash than it spent: $94.6M of free cash flow.
8-K, filed Aug 4, 2026
“Our second quarter results were in line with our expectations, and we remain focused on executing against our full-year plan,” said Faiz…View ↗
8-K, filed Jun 17, 2026
Mr. Gallagher is expected to continue to serve as the Company’s Chief Financial Officer through July 14, 2026 (the “Effective Date”) and…View ↗
8-K, filed May 11, 2026
On May 08, 2026, we completed the sale of our global medical writing and related regulatory services business to Veristat, LLC for cash…View ↗
Growing. Revenue grew 46% in 4 years, from $286.1M in FY2021 to $418.8M in FY2025, about 10% a year.
Artificial intelligence tools
The latest report describes generative artificial-intelligence tools for life-sciences organizations and regulatory writers, alongside regulatory software and services; the older report describes regulatory submissions software and regulatory professionals.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 26, 2026Biosimulation results need to be incorporated into regulatory documents for compelling submissions. Accordingly, we provide regulatory…View ↗
By offering science, technology and consulting services solutions, we provide flexible offerings for life sciences companies of all sizes…View ↗
Chemical research software
The latest report includes Chemaxon tools for chemical search, property prediction and analysis, extending the software offering into chemical research alongside biosimulation across drug discovery and development.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 26, 2026We build our biosimulation technology on first principles of biology, chemistry, and pharmacology with proprietary mathematical algorithms…View ↗
In 2024, Certara acquired Chemaxon, a software company that develops leading software products for chemical property prediction, search…View ↗
Competes with Mathworks, Dassault Systemes, Ansys, Simulations Plus, ICON, Metrum Research, qPharmetra, and Pharmetheus
10-K for FY2025, filed Feb 26, 2026In the biosimulation software market, we compete with other technology companies including Mathworks, Dassault Systemes, Ansys, Simulations…View ↗
Loading...